Weavr Health Corp

Weavr Health Corp., initially incorporated as Boston Microfluidics, Inc. in 2005, operated as a medical device developer focused on democratizing diagnostics through next-generation blood collection technology. The company's core mission was to create user-friendly, reliable devices for at-home blood collection, making testing more accessible and affordable. Weavr Health was acquired by Renegade.bio on March 23, 2023.

The company developed a portfolio of products designed to enable any adult user to collect high-quality, clinical-grade blood samples without the need for a phlebotomist or specialized laboratory equipment. Its flagship product, the Velvet™ blood collection device, was engineered to consistently collect a specific volume of whole blood and separate the sample into plasma and red blood cells. This process allows for more complex analysis and ensures sample stability at room temperature for an extended period, which simplifies logistics for lab transport. Another product, the Silk™ COVID-19 Rapid Antibody Test, was developed to provide rapid, qualitative detection of COVID-19 antibodies. The business model centered on supplying these devices to diagnostic laboratories, healthcare providers, and direct-to-consumer health companies. A significant partnership was established with Labcorp, which utilized the Velvet™ device for its Labcorp OnDemand at-home diabetes risk test, measuring HbA1c from a small blood sample. The collaboration involved an equity investment from Labcorp and resulted in the test being available nationwide after receiving approval from the New York State Clinical Laboratory Evaluation Program.

Before its acquisition, Weavr Health had raised a total of $24.2M in funding through multiple rounds, including investments from Anzu Partners and Labcorp Venture Fund. In January 2023, Nightingale Health acquired a worldwide license and rights to the Velvet™ device, allowing them to manufacture and use it in their preventative health services, having previously been a distributor. This move was strategic for Nightingale to integrate the self-collection technology more tightly into its global service delivery.

Keywords: blood collection device, at-home testing, diagnostic equipment, point of care, remote sample collection, Velvet device, dried blood spot, diagnostics, life sciences, Labcorp partnership, self-collection, phlebotomist-free, clinical-grade samples, medical device, healthcare access, HbA1c testing, remote diagnostics, Nightingale Health, Boston Microfluidics, Anzu Partners